Hyperbaric Oxygen Therapy for CP and HIE: Separating Hope From Evidence

Hyperbaric oxygen therapy is one of the most heavily marketed alternative treatments for cerebral palsy and HIE. The promise is appealing: more oxygen, more brain healing. The evidence is much less encouraging. This article explains what HBOT is, what the research actually shows for CP and HIE, what the FDA and major medical organizations say, and how to think about it as a parent.

What HBOT Is and What It Is FDA-Approved For

HBOT involves a person sitting or lying in a pressurized chamber and breathing 100% oxygen at higher-than-atmospheric pressure (typically 1.5 to 2.5 atmospheres absolute). The oxygen dissolves in plasma and reaches tissues at higher levels than at normal atmospheric pressure. The FDA approves HBOT for specific conditions including decompression sickness, carbon monoxide poisoning, severe anemia, certain wound healing complications (diabetic ulcers, radiation tissue damage), and a few other specific indications. Cerebral palsy and HIE are not on this list. Use for these conditions is considered off-label or experimental.

What the Research Actually Shows

Several randomized controlled trials have examined HBOT for CP. The pivotal trial by Collet and colleagues (Lancet, 2001) randomized 111 children with CP to receive either HBOT or sham (slightly pressurized room air). Both groups improved on motor and cognitive measures, but there was no significant difference between them — suggesting the gains came from attention, expectation, and the experience itself rather than from the oxygen. Subsequent reviews by Cochrane and other systematic reviewers have reached similar conclusions: there is insufficient evidence that HBOT improves outcomes in CP beyond what standard therapy and attention provide. For HIE specifically (in the acute neonatal period), HBOT has been studied in animals but has not become a standard clinical option due to lack of human evidence and practical difficulties.

What Major Organizations Say

Mainstream medical organizations do not recommend HBOT for CP or HIE:

• The American Academy of Neurology does not include HBOT in CP guidelines.
• The American Academy of Pediatrics does not endorse HBOT for CP or HIE.
• The Undersea and Hyperbaric Medical Society, the specialty society for HBOT, lists CP as a non-approved indication.
• The FDA has issued consumer warnings about HBOT being marketed for non-approved conditions including CP and HIE.

The body of clinical practice guidelines is consistent: HBOT is not recommended for CP or HIE.

Why HBOT Continues to Be Marketed

Despite the negative evidence, HBOT clinics continue to advertise to CP and HIE families. Several factors drive this: the appeal of a high-tech treatment that offers hope; testimonial-based marketing without rigorous controls; financial incentives for clinic operators; and the genuine difficulty parents face in evaluating complex medical claims. Some clinics frame HBOT as ‘safe and natural’ (oxygen is essential for life, after all). The placebo and attention effects in studies create real perceived improvements that families and providers attribute to the oxygen.

Costs, Risks, and the Practical Picture

Costs are substantial:

• to + per session
• Protocols often call for 40 to 60 sessions in a course
• Total cost: ,000 to ,000+
• Insurance does not cover HBOT for off-label CP/HIE use
• Travel and lodging add expense for families using out-of-area clinics

Risks include ear barotrauma (the most common complication), oxygen toxicity (rare but serious), claustrophobia, vision changes, and seizures (especially in children with epilepsy). Children with active seizures or significant ear or sinus issues may not be safe candidates.

How to Think About It as a Parent

The honest framing: HBOT for CP or HIE is not supported by current evidence. The improvements families and clinics report appear similar to those seen with sham treatment in controlled trials, suggesting non-specific benefits (attention, expectation, time) rather than oxygen. Spending tens of thousands of dollars on HBOT generally has not been associated with better outcomes than spending the same time and money on intensive evidence-based therapy (PT, OT, SLP, hippotherapy, aquatic therapy, where appropriate). If you are considering HBOT, discuss with your child’s pediatric neurologist, ask the clinic for peer-reviewed efficacy data (not testimonials), and weigh the opportunity cost against other interventions that have clearer evidence.

Evaluating HBOT for Your Child

Use these questions and steps before pursuing HBOT.

What about home soft-shell HBOT chambers?

Home soft-shell chambers operate at much lower pressures than clinic hard-shell chambers and deliver less oxygen at lower pressure. The FDA has not cleared them for medical use. Clinical efficacy is even less established than for clinic HBOT, and home use removes medical supervision. Most pediatric specialists strongly advise against home HBOT chambers for CP or HIE.

Are there cases where HBOT is reasonable for an HIE child?

If a child has an FDA-approved indication unrelated to CP/HIE (such as a non-healing wound), HBOT for that indication may be appropriate. Outside approved indications, mainstream medical opinion does not currently support HBOT for CP or HIE.

Related reading for parents

• Cerebral palsy stem cell therapy: a 2025 guide to cost, success, and legal options
• Erythropoietin and emerging adjunct therapies for HIE: what the research shows
• Cord blood stem cell therapy for HIE: what the science actually shows in 2026
• A guide to the best cerebral palsy treatments in 2025
• Cerebral palsy cooling therapy: what parents need to know